De Gaulle Fleurance recognised in the 2026 Décideurs – Leaders League ranking for Healthcare, Pharma & Biotech
The recognition spans eight distinct categories in the life sciences and healthcare sector, and reflects the depth of the firm’s expertise, from regulatory matters and strategic advisory work to litigation, intellectual property and transactions.
De Gaulle Fleurance ranked “Incontournable” in Regulatory Law
The firm’s regulatory practice, led by partners Frédéric Destal and Cécile Théard-Jallu, is ranked “Incontournable”, the highest level of recognition in this category. The distinction acknowledges the firm’s support for players in the pharmaceutical, medical device and biotechnology industries within a constantly evolving environment, at both French and European level.
De Gaulle Fleurance ranked “Incontournable” in Digital Health Law
The firm is also ranked “Incontournable” for its work on digital health, including artificial intelligence applied to care, connected medical devices and health data, a distinction embodied by Cécile Théard-Jallu. This recognition confirms De Gaulle Fleurance’s position at the intersection of healthcare law and emerging technologies.
De Gaulle Fleurance ranked “Excellent” in Patents, Pharma Litigation, Biotech and Life Sciences
The firm is rated “Excellent” for its support on licensing, co-development and research and development transactions, which are central to industrial partnerships in the pharmaceutical and biotech sectors. The distinction is shared by Francine Le Péchon-Joubert and Cécile Théard-Jallu.
De Gaulle Fleurance ranked “Excellent” in Licensing, Co-development and R&D Agreements
De Gaulle Fleurance is rated “Excellent” for its support on licensing, co-development and research and development transactions, which are central to industrial partnerships in the pharmaceutical and biotech sectors. Once aigain, the distinction is shared by Francine Le Péchon-Joubert and Cécile Théard-Jallu.
De Gaulle Fleurance ranked “Forte notoriété” in Equity Transactions, Joint Ventures and Corporate
De Gaulle Fleurance enjoys a “Forte notoriété” ranking for its work on equity transactions, minority investments and joint ventures in the life sciences sector, a distinction shared by partners Jean-Christophe Amy, François Couhadon and Mireille Mull-Jochem.
De Gaulle Fleurance ranked “Forte notoriété” in Venture Capital
In venture capital, a segment particularly active in financing biotech and medtech companies, the firm also receives a “Forte notoriété” ranking. Jean-Christophe Amy and Henri-Nicolas Fleurance are singled out in this category.
De Gaulle Fleurance ranked “Forte notoriété” in Competition and Distribution
De Gaulle Fleurance is recognised in competition and distribution law as applied to the healthcare sector, a ranking that notably acknowledges the expertise of Cécile Théard-Jallu and Thierry Titone.
De Gaulle Fleurance ranked “Pratique Réputée” in Healthcare Criminal Law
De Gaulle Fleurance’s expertise in healthcare criminal law is recognised as a “Pratique Réputée”, led by partner Albane Lancrenon. The ranking illustrates the firm’s ability to advise on the compliance and criminal liability issues specific to the healthcare sector.
These eight distinctions reflect the collective commitment of De Gaulle Fleurance’s partners and lawyers, and the recognition of their sectoral expertise in healthcare, pharmaceutical and biotechnology law by clients and peers alike.
